EARLY BENEFIT ASSESSMENT OF ORPHAN DRUGS IN GERMANY- METHODOLOGICAL CHALLENGES AND IMPLICATIONS ON REIMBURSEMENT PRICE
May 1, 2016, 00:00
10.1016/j.jval.2016.03.2002
https://www.valueinhealthjournal.com/article/S1098-3015(16)30287-X/fulltext
Title :
EARLY BENEFIT ASSESSMENT OF ORPHAN DRUGS IN GERMANY- METHODOLOGICAL CHALLENGES AND IMPLICATIONS ON REIMBURSEMENT PRICE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30287-X&doi=10.1016/j.jval.2016.03.2002
First page :
A281
Section Title :
Health Care Use & Policy Studies - Health Care Costs & Management
Open access? :
No
Section Order :
1122